INSIGHTS ON CELL & GENE CLINICAL TRIALS

• Personalized Cancer Vaccines: The Science Is Ready. Is the Manufacturing?

  Late-stage melanoma data and long-term survival signals in the hardest solid tumors point to a viable personalized neoantigen vaccine strategy, but a fixed biological timeline strains upstream production.

• How Phase I Trial Ethics Are Changing For Sponsors

  As early efficacy becomes possible in Phase I studies, hope for benefit must be weighed against limited knowledge, reshaping consent language, risk-benefit review, and protocol design for sponsors and IRBs.

• What LSPA's Life Sciences Future Says About The Road Ahead For CGT

  The LSPA’s Life Sciences Future 2026 highlighted how shifting capital, M&A, global competition, and commercial pressures are reshaping CGT.

• Early-Phase Lab Data: Why It Breaks And How To Prevent Risk

  Learn why lab data systems built quickly in early-phase trials tend to outlast their usefulness, quietly accumulating inconsistencies that surface only when scrutiny intensifies later in a study.

• Effectively Tailoring Treatments Based On Genetic & Molecular Profiling

  Precision medicine is transforming hematology-oncology care by matching treatments to the distinct genetic and molecular profiles of each patient.

• Why U.S. Sponsors Should Conduct Clinical Trials In Australia

  Faster approvals, refundable tax offsets, and a large patient population raise a pointed question: does Australia now outperform U.S. sites for early trial start-up?

• Selecting A Central Lab Network For Radiopharmaceutical Readiness

  A wave of late-stage radiopharmaceutical trials is straining lab infrastructure concentrated in a handful of academic centers, limiting site diversity, expertise, and trial capacity nationwide.

• The Future Of Clinical Trials: 7 Trends Redefining FSP Models By 2030

  Learn why factors like decentralized trials and tighter global rules are pushing sponsors to favor fewer, deeply integrated, tech-driven partners over traditional staffing models for clinical outsourcing.

• The Answer To Advance Your Allogeneic CAR-T Cell Clinical Trial

  Dozens of assays, a shifting sample analysis plan, and a network of specialty labs: see how coordinated oversight kept an allogeneic CAR-T trial on track.

• "How I Feel" – The Critical Role Of The Patient Perspective And How To Collect It

  Not sure how to capture what patients really experience? Explore five research methods, their strengths and limitations, and how early patient insight can sharpen trial design and development decisions.